Dyadic International Inc (DYAI)

[tykundegex]

MEDIF can create/generate more revenue as they have the capacity for it already today. DYAI has to "find" theirs though licensing. The counterpart to that is that MEDIF is "limited" by their production capacity, whereas DYAI has no limits (except "the sky" as the CEO himself says).

I'm not sure Nasdaq uplist will help immediately as until or unless they announce some revenue-producing deals, there is still considerable risk here. But if they do get traction, then it's likely to multiply quickly, along with the share price IMO.

This kind of business screams acquisition by BP or a CDMO. Or they may play the long game and build their C1 platform into a formidable licensing cash cow.

(agreed there is 10x ++ to this stock if the platform can do what they expect .. which all signs already point to it doing)